Potential Medication Error Risks With Investigational Drug Container Labels

FDA and the Reagan-Udall Foundation for the FDA held a virtual public meeting on the potential medication error risks with investigational drug container labels. We solicited input from stakeholders (e.g., sponsors, investigators, clinical sites, entities that supply or label investigational drugs, and study participants) on the risk of medication errors related to the content and format of information on investigational drug container labels, the prevalence and nature of medication errors, and practices that might minimize the potential for such errors.

Industry Voices—Harnessing a watershed moment for real-world data - Fierce Healthcare

Across every facet of life, 2020 tested our resolve and resilience. COVID-19 stretched our systems to the breaking point, exposing inexcusable gaps and limitations in our systems. As a force of creative destruction and reinvention, however, it also prompted new conversations, broke through barriers and accelerated the pace of innovation. This has been as much the case in the realm of real-world data (RWD) as it has anywhere.